Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Sanara MedTech (SMTI) over the last 13 years, with Q3 2025 value amounting to $208414.0.

  • Sanara MedTech's Gains from Investment Securities rose 57202.14% to $208414.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $208414.0, marking a year-over-year increase of 57202.14%. This contributed to the annual value of $192783.0 for FY2024, which is 10532.42% up from last year.
  • As of Q3 2025, Sanara MedTech's Gains from Investment Securities stood at $208414.0, which was up 57202.14% from $175686.0 recorded in Q2 2025.
  • Sanara MedTech's 5-year Gains from Investment Securities high stood at $1.4 million for Q1 2023, and its period low was $11500.0 during Q2 2021.
  • Its 5-year average for Gains from Investment Securities is $283596.9, with a median of $164137.5 in 2025.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 198928.2% in 2021, then plummeted by 9899.87% in 2022.
  • Sanara MedTech's Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then crashed by 99.0% to $13518.0 in 2022, then soared by 779.66% to $118912.0 in 2023, then crashed by 71.1% to $34370.0 in 2024, then skyrocketed by 506.38% to $208414.0 in 2025.
  • Its Gains from Investment Securities stands at $208414.0 for Q3 2025, versus $175686.0 for Q2 2025 and $152589.0 for Q1 2025.